{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:59:37Z","timestamp":1780714777443,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Amgen Canada Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40744-024-00641-w","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T08:02:17Z","timestamp":1709107337000},"page":"443-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03608657","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-2731","authenticated-orcid":false,"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1721-190X","authenticated-orcid":false,"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9310-0584","authenticated-orcid":false,"given":"Maqbool","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2923-9862","authenticated-orcid":false,"given":"Sabeen","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1417-1075","authenticated-orcid":false,"given":"Jennifer","family":"Jelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4853-7445","authenticated-orcid":false,"given":"Anne-Julie","family":"Gaudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0464-871X","authenticated-orcid":false,"given":"Manprit","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-369X","authenticated-orcid":false,"given":"John S.","family":"Sampalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"10","key":"641_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"641_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","volume":"27","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118\u201326.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"641_CR3","first-page":"809","volume":"17","author":"DD Gladman","year":"1990","unstructured":"Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17(6):809\u201312.","journal-title":"J Rheumatol"},{"issue":"2","key":"641_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45(2):151\u20138.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"641_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/03009742.2020.1803398","volume":"50","author":"FR Kasiem","year":"2021","unstructured":"Kasiem FR, Luime JJ, Vis M, et al. Lessons learned from clinical phenotypes in early psoriatic arthritis: the real-world Dutch south west Early Psoriatic ARthritis study. Scand J Rheumatol. 2021;50(2):124\u201331.","journal-title":"Scand J Rheumatol"},{"issue":"10012","key":"641_CR6","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489\u201398.","journal-title":"Lancet"},{"issue":"12","key":"641_CR7","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1136\/ard.2011.150938","volume":"70","author":"DD Gladman","year":"2011","unstructured":"Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"641_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6\u00a0months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"641_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","volume":"73","author":"E Theander","year":"2014","unstructured":"Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"641_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"641_CR11","doi-asserted-by":"crossref","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.","DOI":"10.3390\/ijms21051690"},{"key":"641_CR12","unstructured":"Otezla [product monograph]. Mississauga, ON, Canada: Amgen Canada Inc.; August 2020."},{"issue":"6","key":"641_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/acr.24134","volume":"72","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Gladman DD, Ogdie A, et al. Treatment-to-target with apremilast in psoriatic arthritis: the probability of achieving targets and comprehensive control of disease manifestations. Arthritis Care Res (Hoboken). 2020;72(6):814\u201321.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"641_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3899\/jrheum.210906","volume":"49","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Kavanaugh A, Ogdie A, et al. Baseline disease activity predicts achievement of cDAPSA treatment targets with apremilast: phase\u00a03 results in DMARD-naive patients with psoriatic arthritis. J Rheumatol. 2022;49:694\u20139.","journal-title":"J Rheumatol"},{"issue":"2","key":"641_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s12325-021-02016-x","volume":"39","author":"K de Vlam","year":"2022","unstructured":"de Vlam K, Toukap AN, Kaiser MJ, et al. Real-world efficacy and safety of apremilast in Belgian patients with psoriatic arthritis: results from the prospective observational APOLO study. Adv Ther. 2022;39(2):1055\u201367.","journal-title":"Adv Ther"},{"issue":"1","key":"641_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Kleyn CE, Conrad C, et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35(1):123\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"641_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001170","volume":"6","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Ca\u00f1ete JD, Perrotta FM. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020;6(1):e001170.","journal-title":"RMD Open"},{"key":"641_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"641_CR19","doi-asserted-by":"publisher","first-page":"R170","DOI":"10.1186\/ar2859","volume":"11","author":"V Strand","year":"2009","unstructured":"Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1\u00a0year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther. 2009;11(6):R170.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"641_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/ard.2006.057901","volume":"66","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis. 2007;66(2):163\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"641_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","volume":"86","author":"L Stein Gold","year":"2022","unstructured":"Stein Gold L, Papp K, Leonardi C, et al. Efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis: results of a phase\u00a03, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022;86(1):77\u201385.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"641_CR22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461\u20135.","journal-title":"J Rheumatol"},{"issue":"3","key":"641_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.semarthrit.2018.05.010","volume":"48","author":"P Mease","year":"2018","unstructured":"Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: importance and challenges. Semin Arthritis Rheum. 2018;48(3):436\u201348.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"641_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase\u00a03 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"641_CR25","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo M, Myerson GE, Fleischmann R, et al. A phase\u00a0III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE\u00a02 trial. J Rheumatol. 2016;43(9):1724\u201334.","journal-title":"J Rheumatol"},{"issue":"6","key":"641_CR26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"CJ Edwards","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase\u00a0III, randomised, controlled trial (PALACE\u00a03). Ann Rheum Dis. 2016;75(6):1065\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"641_CR27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","volume":"57","author":"AF Wells","year":"2018","unstructured":"Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE\u00a04 trial. Rheumatology (Oxford). 2018;57(7):1253\u201363.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"641_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","volume":"21","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE\u00a01\u20133 pooled analysis. Arthritis Res Ther. 2019;21(1):118.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"641_CR29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/jdv.14832","volume":"23","author":"E Papadavid","year":"2018","unstructured":"Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;23(7):1173\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"641_CR30","first-page":"1240","volume":"16","author":"A Armstrong","year":"2017","unstructured":"Armstrong A, Levi E. Real-world clinical experience with apremilast in a large US retrospective cohort study of patients with moderate to severe plaque psoriasis. J Drugs Dermatol. 2017;16(12):1240\u20135.","journal-title":"J Drugs Dermatol"},{"key":"641_CR31","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Merola JF, Cirulli J, et al. Characteristics of patients with psoriasis treated with apremilast in the Corrona Psoriasis Registry. Dermatol Ther (Heidelb). 2021;11(1):253\u201363.","DOI":"10.1007\/s13555-020-00479-4"},{"issue":"6","key":"641_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1203475420936652","volume":"24","author":"Y Poulin","year":"2020","unstructured":"Poulin Y, Beauchemin C, Royer C, et al. Real-world experience with apremilast in the treatment of adults with moderate to severe plaque psoriasis in Qu\u00e9bec: a claims-based analysis of drug utilization and healthcare resource utilization. J Cutan Med Surg. 2020;24(6):573\u201387.","journal-title":"J Cutan Med Surg"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00641-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00641-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00641-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:37:02Z","timestamp":1709836622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00641-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00641-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vinod Chandran has received grant\/research support from and\/or served as a consultant for AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB Pharma. His spouse is an employee of AstraZeneca. Louis Bessette has received grant\/research support from and\/or served as a consultant for AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Pfizer, Sanofi, Novartis, and UCB Pharma. Carter Thorne has served on an advisory board for AbbVie, Amgen Inc., Celgene, Eli Lilly, Medexus\/Medac, Merck, Novartis, Pfizer, Sandoz, and Sanofi; and has served as a consultant for Centocor, Medexus\/Medac, and Merck. Maqbool Sheriff has served on an advisory board and received honoraria from AbbVie, Celgene, Eli Lilly, Janssen, Merck, Pfizer, and Sandoz. Proton Rahman has served as a speaker for and received honoraria from AbbVie, Amgen Inc., Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB Pharma. Dafna D. Gladman has received grant\/research support from or served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. Sabeen Anwar\u00a0has received grant\/research support from AbbVie, Amgen Inc., Eli Lilly, Janssen, and Pfizer; and has served as a speaker or consultant for AbbVie, Amgen Inc., Bristol Myers Squibb, Novartis, and Pfizer. Jennifer Jelley, Anne-Julie Gaudreau, and Manprit Chohan are employees of and stockholders in Amgen Inc. John S. Sampalis is an employee of JSS Medical Research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"APPRAISE was conducted in accordance with the Declaration of Helsinki\u2019s general ethical principles with the study protocol approved by the Canadian Shields Ethics Review Board (#18-05-00) and the University Health Network Research Ethics Board (18-6022). Informed written consent was obtained from each patient prior to any study-related procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}